Dyne Therapeutics (DYN) Interest Coverage Ratio (2019 - 2026)
Dyne Therapeutics' (DYN) quarterly Interest Coverage Ratio came in at 2.54 in Q1 2026, up 86.42% year-on-year from 1.36 in Q1 2025, and up 94.44% on a QoQ basis from 45.61 in Q4 2025.
Dyne Therapeutics (DYN) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has 8 years of Interest Coverage Ratio data on file, last reported at 2.54 in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 86.42% year-over-year to 2.54 in Q1 2026; TTM through Mar 2026 was 9.54, a 84.26% increase from a year earlier, with the FY2025 full-year figure at 8.87, down 644.58% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 2.54, up from 45.61 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for DYN reached as high as 0.35 in Q4 2022 and fell as low as 1231.82 in Q2 2025.
- Historically, Interest Coverage Ratio has averaged 85.83 across 5 years, with a median of 2.53 in 2026.
- Across the five-year window, Interest Coverage Ratio jumped 99.86% in 2022 and plunged 304624.69% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.35 in 2022, then tumbled by 31.42% to 0.46 in 2023, then slumped by 4098.65% to 19.5 in 2024, then plunged by 133.96% to 45.61 in 2025, then soared by 94.44% to 2.54 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 2.54 in Q1 2026, 45.61 in Q4 2025, and 39.22 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Dyne Therapeutics | 3.94 Bn | 3.94 Bn | - | -2.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.54 |
| Dec 31, 2025 | -45.61 |
| Sep 30, 2025 | -39.22 |
| Jun 30, 2025 | -1,231.82 |
| Mar 31, 2025 | -18.68 |
| Dec 31, 2024 | -19.50 |
| Jun 30, 2024 | -0.40 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | -0.46 |
| Sep 30, 2023 | -4.02 |
| Jun 30, 2023 | -2.52 |
| Mar 31, 2023 | -1.41 |
| Dec 31, 2022 | -0.35 |
| Sep 30, 2022 | -0.99 |
| Jun 30, 2022 | -3.91 |
| Mar 31, 2022 | -1.37 |
| Dec 31, 2021 | -255.96 |
| Sep 30, 2021 | -0.70 |
| Jun 30, 2021 | -0.32 |
| Mar 31, 2021 | -0.42 |